###### Strengths and limitations of this study

-   This study was carried out in a single Institution of the Apulia region. Cases were referred by Fertility Clinics of the same region.

-   The reference cohort of pregnant women who delivered at the same Institution was representative of the general population from the same geographical area, as maternal age and the number of live births were comparable in the two populations.

-   In the reference cohort, the number of vein thromboses may be under-represented in respect of the general pregnant population, as some cases may not be admitted to the hospital.

-   We were not able to evaluate in the reference cohort the influence of other risk factors and, in the study group, that of change in assisted reproductive technologies practice during a rather long period (2002--2011).

Introduction {#s1}
============

It is well known that pro-coagulant changes occurring during normal pregnancy cause an increased risk of venous thromboembolism (VTE). Previous studies have found that VTE after a spontaneous conception is slightly more than 1 of 1000 pregnant women.[@R1] [@R2] In women undergoing assisted reproductive technologies (ART), medical ovarian stimulation is thought to increase thrombotic risk. However, available data about the magnitude and the duration of VTE risk in ART are conflicting. A review of several published case reports concluded that in in-vitro fertilisation (IVF) the VTE risk is comparable to that of spontaneous conceptions.[@R3] Similarly, a more recent Danish register-based cohort study did not find an increased risk after IVF treatment in unsuccessful cycles.[@R4] Nevertheless, an increased risk in successful IVF cycles was very recently reported, and the risk seems to be significantly higher during the first trimester.[@R4] An important role as a risk factor for VTE is played by ovarian hyperstimulation syndrome (OHSS) occurring during and after an ART procedure, with supraphysiological oestradiol levels that sometimes can result. During ovarian stimulation, the coagulation and fibrinolytic systems are activated; this activation appears to be exaggerated and prolonged with the development of OHSS.[@R8] This syndrome is a systemic disorder resulting from vasoactive products released by hyperstimulated ovaries. Haemoconcentration, altered coagulation system and reduced venous return secondary to enlarged ovaries, ascites and immobility are likely to be important determinants for the increased risk of venous thrombosis in women with OHSS. Thrombotic events have also been reported to occur weeks after OHSS has resolved.[@R9] It has been calculated that OHSS increases until 100-fold the risk of VTE.[@R6] Inherited or acquired thrombophilias, body mass index (BMI), increasing age and reduced mobility could further increase this risk. A previous large study carried out in our centre showed that age over 39 and mild hyperhomocysteinaemia are strongly associated with the occurrence of thrombotic events during ART, while the impact of common inherited causes of thrombophilia was not statistically relevant.[@R10] A similar result was shown by Ricci *et al*[@R11] in a prospective cohort of nulliparous women undergone ART cycles: neither the presence of factor V Leiden (FVL) nor the FIIA20210 prothrombin mutation (PTm) gene variants influenced the thrombotic risk. In the present study, we prospectively evaluated the incidence of VTE in successful ART cycles and, for the first time in an Italian cohort, compared it with that of the general population conceiving spontaneously.

Patients and methods {#s2}
====================

We identified 998 women candidate to ART consecutively referred by local Fertility Clinics to our Unit from April 2002 to July 2011. At that time, detailed information on maternal age, BMI, smoking status, causes of infertility, personal history of obstetric complications and VTE was collected. All the women were investigated for the presence of inherited (FVL, PTm and deficiencies in protein S and C and antithrombin) and acquired (lupus anticoagulant (LA), anticardiolipin antibodies (aCL)) thrombophilias. Follow-up information was obtained during the check-up and/or by phone interviews. The prescription of aspirin and/or LMWHs was verified by reviewing medical records. For each woman, the following information was collected: cycles number, type of ART procedure (IVF and intracytoplasmatic sperm injection (ICSI), or intrauterine injection (IUI)), occurrence of clinical pregnancy (defined as the ultrasonographic visualisation of one or more gestational sacs and fetal heart beat),[@R12] pregnancy loss (defined as a loss occurring before/at 20 weeks of gestation), intrauterine fetal death (a loss occurring after 20 weeks), live birth (the delivery of a live newborn), presence of OHSS, obstetric and thromboembolic complications. Diagnosis of VTE or superficial vein thrombosis (SVT) was objectively confirmed by Doppler ultrasonography, ventilation-perfusion lung scanning or pulmonary angiography.[@R8] Only cycles starting with ovarian stimulation and ending with embryo-transfer/IUI were considered.

We identified all women who had undergone at least one ART cycle and achieved at least one clinical pregnancy after the procedure. However, for final analysis, in case of more than one successful cycle, only the first pregnancy was considered. Similarly, in the reference cohort, when the same woman delivered more than once, only the first pregnancy was computed.

Between January 2010 and December 2012, 3527 women gave birth at our hospital; after the exclusion of 155 pregnancies of those who delivered in this period more than once and 33 pregnancies obtained by means of ART, 3339 pregnancies were considered as the reference group. From 2010, an electronic database is available in our Institution that includes validated information on the pregnancy, delivery and neonatal periods. We obtained information on the diagnoses of pregnancy-related VTE by linkage to our Institutional patient register, an administrative database containing information on the dates of admission and discharge and the main diagnosis. The choice to consider also SVT depends on the reported association with deep-vein thrombosis, as a high rate of pulmonary embolism in patients with saphenous vein thrombosis and no obvious deep vein involvement has been described.[@R13]

Diagnoses were recorded according to the International Classification of Diseases, 9th revision (ICD-9): codes 325, 415.1, 451, 452, 453, 671.3, 671.4, 671.5, 671.9, 673.2, 673.3. In order to evaluate whether our reference group was representative of the regional population, we compared median age and the number of live births of women who delivered at our Hospital and women who delivered in a similar time lapse (2008--2010) in the same Italian region (Apulia). This last information was extracted from the Italian birth register at the National Board of Health and Welfare.[@R14] The study was approved by the local ethics committee, and participants gave their written informed consent for present and future use of clinical data.

Laboratory tests {#s2a}
----------------

Blood samples were collected in 3.8% trisodium citrate and centrifuged at 2000 g for 15 min to obtain platelet-poor plasma, which was frozen and stored in small aliquots at −70°C until tested. Antiphospholipid antibodies---LA and IgG, IgM aCL (QUANTA Lite, INOVA Diagnostics, San Diego, California, USA)---antithrombin and protein C (Berichrom Antithrombin and Protein C amidolytic assays, Behring, Germany) and free protein S (IMUCLONE Protein S ELISA, American Diagnostica, Stamford, Connecticut, USA) were determined in all patients. A confirmed presence of antiphospholipid antibodies was defined according to SSC criteria,[@R15] or the concurrent presence of more than one. DNA was extracted from peripheral blood leucocytes according to standard protocols.

FVL and PTm genotyping was performed by a TaqMan (Applied Biosystems, Foster City, California, USA) probe-based real-time PCR technique.[@R16]

Statistical analysis {#s2b}
--------------------

All the analyses were performed using SPSS V.11.0 (SPSS Inc, Chicago, Illinois, USA). The significance of any difference in means was evaluated by non-parametric tests, whereas the significance of any difference in proportions was tested using the Fisher exact test or by χ^2^ statistics as appropriate. OR and 95% CIs were calculated.

Results {#s3}
=======

A flow chart of the study cohort is shown in [figure 1](#BMJOPEN2015008213F1){ref-type="fig"}. Overall, we identified 234 women who achieved a clinical pregnancy after an ART cycle. Median BMI was 22.4 kg/m^2^, most women did not smoke (79.5%) and 10.3% carried congenital or acquired thrombophilias ([table 1](#BMJOPEN2015008213TB1){ref-type="table"}). As far as severe thrombophilias are concerned, two women showed protein S deficiency (one combined with FV Leiden) and one a confirmed presence of antiphospholipid antibodies. The frequencies we observed were not significantly different from those found in a general population from the same ethnic background.[@R17]

###### 

Baseline characteristics of the study sample (N=234)

  ---------------------------------- -------------------
  Age years, median (range)          34 (23--46)
  BMI, median (range)                22.4 (16.7--35.9)
  Smoking habits, n/N (%)            
   Unknown                           7 (3)
   No smokers                        186 (79.5)
   1--10 cigarettes per day          31 (13.2)
   10--20 cigarettes per day         7 (3)
   \>20 cigarettes per day           1 (0.4)
   Not provided                      2 (0.9)
  Infertility factors, n/N (%)       
   Male                              92 (39.3)
   Female                            50 (21.3)
   Unexplained                       79 (33.8)
   Mixed                             10 (4.3)
   Unknown                           3 (1.3)
  FVL, n/N (%)                       11 (4.7)
  PTm, n/N (%)                       10 (4.3)
  Severe thrombophilias\*, n/N (%)   3 (1.3)
  ---------------------------------- -------------------

\*Either homozygosis for FVL or PTm; double mutation, FVL or PTm and/or natural anticoagulants deficiency.

BMI, body mass index; FVL, factor V Leiden; PTm, prothrombin mutation.

![Study cohort (April 2002--July 2011). ART, assisted reproductive technologies.](bmjopen2015008213f01){#BMJOPEN2015008213F1}

Overall, these women were exposed to a total of 684 ART cycles, 75 IUI and 609 IVF/ICSI with a clinical pregnancy rate of 33.3% (n=25) and 41% (n=250), respectively. Thirty-five women had more than one clinical pregnancy; in this case, we considered only the first pregnancy; thus, 234 clinical pregnancies were included in the final analysis. One hundred and forty-seven (62.8%) pregnancies resulted in live births. [Table 2](#BMJOPEN2015008213TB2){ref-type="table"} shows clinical features of women who suffered from VTE: two of three women tested negative for thrombophilia, while one had a PTm in heterozygosis; the latter had age and BMI as additional risk factors. None presented a family history of VTE. In one case, a SVT in the left leg was recorded during prophylaxis with LMWH in a patient suffering from erythema nodosum; later on, this patient also had a recurrence of SVT in the right leg in a following pregnancy during prophylaxis with LMWH. Both the events occurred during the first trimester.

###### 

Characteristics of women from the study cohort experiencing venous thrombosis

  Patients   Age at event   BMI    Thrombophilia or OHSS   Additional risk factors   Cycle   Type of event                                         Antithrombotic prophylaxis
  ---------- -------------- ------ ----------------------- ------------------------- ------- ----------------------------------------------------- ----------------------------
  1          30             22.3   No                      No                        1       SVT in the left leg at 12 weeks of pregnancy          LMWH\*
  2          38             20.4   No                      No                        3       PE during twin pregnancy ended with IUFD (22 weeks)   None
  3          40             35.9   PTm heterozygous        No                        3       DVT in the right leg at 18 weeks of pregnancy         None

\*Started when pregnancy test was positive.

BMI, body mass index; DVT, deep vein thrombosis; LMWH, low-molecular-weight heparin; IUFD, intrauterine fetal death; PE, pulmonary embolism; OHSS, ovarian hyperstimulation syndrome; PTm, prothrombin mutation; SVT, superficial vein thrombosis.

An antithrombotic prophylaxis with LMWH alone or combined with low-dose aspirin was prescribed in 23/234 (9.8%) women; among them, 8/23 (34.8%) were thrombophilic (three FVL heterozygotes, three PTm heterozygotes, one carried a protein S deficiency combined with FVL and one a confirmed presence of antiphospholipid antibodies). Among non-treated women (n=211), 16 carried thrombophilia: 8 were FVL heterozygotes, 7 PTm heterozygotes and 1 carried a protein S deficiency. When we compared the incidence of thrombotic events in the presence or absence of prophylaxis with LMWH, we found no significant difference between the groups (thromboses: 1/23 vs 2/211, p: ns). The median age of the whole group of cases was 34 years (23--46) and was not significantly different from those who were prescribed LMWH with/without low-dose aspirin (35 years, range 27--42 years) and the remaining ones (34 years, range 23--46 years).

Among 234 successful cycles, 10 (4.3%) were complicated by OHSS. An antithrombotic treatment with LMWH was prescribed because of a diagnosis of OHSS in 3 of 23 (13%) treated cases; in the remaining cases, the indication of an antithrombotic treatment was not indicated by Fertility Centres. On the other hand, an OHSS was recorded in 7 of 211 (3.3%) untreated pregnancies.

A cohort of 3339 women (median age 31 years, range: 14--46, no significant difference vs cases) who consecutively gave birth at our Hospital after spontaneous conception from January 2010 to December 2012, used as a reference population, showed no significant difference in maternal age and number of live births in respect of the general population of women who delivered between January 2008 and December 2010 in the same geographical area (Apulia region) ([table 3](#BMJOPEN2015008213TB3){ref-type="table"}). In this reference cohort, a total of 11 vein thromboses were observed: 6 deep vein thrombosis and 5 SVT ([table 4](#BMJOPEN2015008213TB4){ref-type="table"}). The two-tailed Fisher exact test showed a trend towards statistical significance (p: 0.06, OR: 3.9, 95% CI 0.87 to 15.3). After the exclusion of superficial thromboses in both the groups, we found that the incidence of VTE in our population of women who had undergone ART was 2/234 pregnancies (8.5 ‰), whereas that in our reference population delivering in our hospital was 6/3339 (1.8 ‰) (p: 0.09). Furthermore, when we excluded those women who had had a previous VTE (patients 2 and 9 of the reference cohort, [table 4](#BMJOPEN2015008213TB4){ref-type="table"}), the two-tailed Fisher exact test approached statistical significance (p: 0.054; OR: 7.2, 95% CI 0.91 to 45.6).

###### 

Age and live births in the reference cohort and general population from the same geographical area

                                                                                 Maternal age   Live births number                
  ------------------------------------------------------------------------------ -------------- -------------------- ------ ----- ---------
  Reference cohort (n=3339), % 2010--2012                                        3.7            34.4                 55.1   6.8   3451
  General population from the same geographical area (n=106 265), % 2008--2010   2.3            32.4                 59.5   5.8   107 461

###### 

Characteristics of women from the reference cohort experiencing venous thrombosis

  Patient   Age at event   BMI    Thrombophilia                     Additional risk factors                  Type of event                                Antithrombotic prophylaxis
  --------- -------------- ------ --------------------------------- ---------------------------------------- -------------------------------------------- ----------------------------
  1         31             37.1   No                                No                                       Antepartum SVT in the left leg               None
  2         33             18.3   No                                Previous SVT after Caesarean section     Antepartum DVT in the left leg               None
  3         28             17.3   FVL heterozygous                  Family history for VTE                   Antepartum (37 weeks) DVT in the right leg   LMWH\*†
  4         33             NA     NA                                No                                       Postpartum SVT in the right leg              None
  5         37             NA     NA                                No                                       Postpartum bilateral SVT                     None
  6         43             NA     NA                                No                                       Antepartum DVT in the left leg               None
  7         22             NA     NA                                No                                       Postpartum DVT in the left leg               None
  8         35             NA     NA                                No                                       Postpartum bilateral SVT                     None
  9         36             21.3   FVL heterozygous+ PC deficiency   Previous DVT during oral contraceptive   Antepartum (21 weeks) DVT in the left leg    LMWH\*‡
  10        33             18.7   FVL heterozygous                  No                                       Antepartum DVT in the left leg               None
  11        35             NA     NA                                No                                       Postpartum SVT in the right leg              None

\*Started when pregnancy test was positive.

†Treatment withdrawn for physician\'s choice at 32 weeks.

‡Treatment withdrawn for patient\'s choice at 20 weeks.

BMI, body mass index; DVT, deep vein thrombosis; FVL, factor V Leiden LMWH, low-molecular-weight heparin; NA, not available; PC, protein C; PE, pulmonary embolism; SVT, superficial vein thrombosis.

Discussion {#s4}
==========

To the best of our knowledge, this is the first attempt in Italy to calculate VTE incidence in pregnancies after ART as compared to the risk of pregnancies after natural conception. We found a slightly higher VTE incidence in pregnancies after ART than in those after natural conception. Our findings, although showing only a trend towards statistical significance, most likely due to the small sample size, are in agreement with those recently obtained in other Countries.[@R5] However, the higher first trimester VTE incidence recorded in previous studies was not confirmed by the present findings; in fact, two of three VTE occurred after the end of the 14th gestational week ([table 2](#BMJOPEN2015008213TB2){ref-type="table"}).

During the ovulation induction, a haemoconcentration occurs, which with high oestrogen levels and an increased number of small ovarian follicles can predispose to the development of OHSS, which is an important trigger for VTE.[@R8]

In our study, the role of other potential risk factors, such as the type of drugs (ie, gonadotropins) used for ovulation induction, was not evaluated. The role of inherited and acquired thrombophilias, well established conditions predisposing to thrombosis, seems to be rather weak for pregnant women after ART, as only one of them showed a common cause of thrombophilia (PTm). On the other hand, among the remaining 23 thrombophilic women, none developed a VTE; no VTE was recorded among women carrying the most severe thrombophilias (n=3). We cannot conclude about a potential benefit of antithrombotic prophylaxis in the group carrying thrombophilia, due to the small sample size.

Overall, 10 (4.3%) OHSS were recorded; this percentage is not significantly different from that reported in other series (15); 3 of 10 OHSS were treated with LMWH, as suggested by the current guidelines,[@R9] [@R18] [@R19] while the remaining seven cases were not treated; we are not able to investigate the reason for the lack of treatment, but we can hypothesise that they were moderate or mild forms of OHSS. Some limitations of our study need to be considered. First, there is a lack of detailed data on lifestyle factors such as smoking, obesity and thrombophilic status in the reference cohort; it was not possible to obtain these data, as they were extracted from an administrative database. Therefore, we were not able to compare for all possible variables the two groups of women. However, the reference cohort was found to be representative of the general population from the same geographical area, as maternal age and the number of live births were comparable in the two populations. Second, we cannot exclude that in our reference cohort the number of vein thromboses may be under-represented in respect of the general pregnant population, as some cases may not be admitted to the hospital. However, this possible bias is also present in our group of outpatients; in addition, the incidence we recorded in our reference cohort was found to be similar to that expected in the general population of pregnant women (1: 1000).[@R1] [@R2] Third, we cannot exclude that during the quite long period of observation (2002--2011) the ART practice has changed; however, it is likely that the number of adverse events is reduced, as improvements were seen in maternal and neonatal outcomes.[@R20] On the other hand, the improvement of standard care allowed for a substantial fall in the rate of VTE in general pregnant population. The lack of confounders' control is another limitation and depends on the observational nature of the study and the sample size.

In conclusion, an increased, although not significant, absolute risk of vein thrombosis during pregnancies after ART was found. Further studies aimed at identifying women who could potentially benefit from an antithrombotic prophylaxis are needed.
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